Market revenue in 2023 | USD 120.0 million |
Market revenue in 2030 | USD 183.1 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 58.08% in 2023. Horizon Databook has segmented the Singapore inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
Approval of new drugs to gain market share is a key strategy adopted by the companies in Singapore. For instance, in June 2022, Yuflyma was launched by Cellario for the treatment of severe to moderate Crohn’s disease and ulcerative colitis in adult patients. However, the therapy is approved for usage in patients that do not respond to conventional treatments.
This limits the growth scope for these novel drugs. ABRILADA by Pfizer was approved in August 2022 for use in Crohn’s disease in pediatric patients. However, increasing R&D activities by local players for the development of biosimilars are expected to fuel the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Singapore inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Singapore inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account